

Fourth Quarter & Full-Year 2022 Earnings Release

February 1, 2023



FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES

Statements in this release that are not strictly historical, including statements regarding the impact of the COVID-19 pandemic, business and acquisition opportunities, impact of acquisitions and dispositions, leadership succession, anticipated financial results, economic conditions, industry trends, future prospects, shareholder value, and any other statements identified by their use of words like "anticipate," "expect," "believe," "outlook," "guidance," or "will" or other words of similar meaning are "forward-looking" statements within the meaning of the federal securities laws. These factors include, among other things: deterioration of or instability in the economy, the markets we serve, international trade policies and the financial markets, the spread of, and the remedial effort related to COVID-19, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, changes in trade relations with China, contractions or lower growth rates and cyclicality of markets we serve, competition, changes in industry standards and governmental regulations, our ability to recruit and retain key employees, our ability to successfully identify, consummate, integrate and realize the anticipated value of appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to develop and successfully market new products, software, and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, contingent liabilities relating to acquisitions and divestitures, impact of changes to tax laws, our compliance with applicable laws and regulations and changes in applicable laws and regulations, risks relating to international economic, geopolitical, including war and sanctions, legal, compliance and business factors, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, the impact of our debt obligations on our operations, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to adequately protect our intellectual property rights, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, commodity costs and surcharges, security breaches or other disruptions of our information technology systems, adverse effects of restructuring activities, risk related to tax treatment of the Separation, impact of our indemnification obligation to Vontier, impact of changes to U.S. GAAP, labor matters, and disruptions relating to man-made and natural disasters and climate change. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2021. These forward-looking statements speak only as of the date of this release, and Fortive does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

This presentation may contain references to financial measures not presented in accordance with generally accepted accounting principles ("GAAP"). We have not reconciled forward-looking outlook regarding non-GAAP measures, other than adjusted EPS, because any corresponding GAAP measures and the reconciliations thereto would require us to make estimates or assumptions with precision about acquisitions, capital and other expenditures and similar adjustments during the relevant period. Information required by Regulation G with respect to historical non-GAAP financial measures and for forward-looking adjusted EPS are set forth in the appendix to this presentation.

All financial metrics relate only to the continuing operations, and all growth or period changes refer to year-over-year comparisons unless otherwise stated. Please refer to the corresponding Form 10-K for the year ended December 31, 2022 for additional details relating to the financial results and performances discussed in this presentation.


Q4 & FY 2022 FINANCIALS AND HIGHLIGHTS

FORTIVE

A STRONG FINISH TO AN OUTSTANDING YEAR

Q4 & FY 2022 FINANCIALS

HIGHLIGHTS



Adj. Earnings

Per Share

Q4 \$0.88

FY \$3.15

Adj. Operating Profit Margin

Q4 25.5% FY 24.3%

Free Cash Flow

Q4 \$428M FY \$1,207M



14% core revenue growth in Q4 | 10% in FY'22 High-quality portfolio & strong execution deliver upside



50 bps adj. GMX; 110 bps adj. OMX in Q4 | 30 bps adj. GMX; 120 bps adj. OMX in FY'22

• Leading brands & power of FBS enable margin expansion



11% adj. EPS growth in Q4 | 15% in FY'22 • Delivering above high-end of initial 2022 outlook




62% growth in free cash flow in Q4 | 28% in FY'22

Robust compounding model yielding results

DELIVERED AHEAD OF EXPECTATIONS IN CHALLENGING "SHOW ME" YEAR

DIFFERENTIATED PERFORMANCE IN 2022

COMPARING FAVORABLY TO PEERS ON HEADLINE FINANCIAL METRICS





SUMMARY

- Significant progress delivering on our vision and strategy over the last 6 years
- Portfolio today consists of higher growth and more profitable businesses aligned to more enduring secular trends
- Strong 2-year stack performance of 20% core growth and +330bps adj. OMX
- Compounding cash flow off higher base, a key FTV differentiator and value driver


2022 PERFORMANCE HIGHLIGHTS BENEFITS OF PORTFOLIO TRANSFORMATION AND EXECUTION

* Compounder avg. includes AME, DOV, IEX, ROP using actual numbers for companies that have reported and Factset consensus for those that have not. ** Industrial peer average includes EMR, ETN, HON, IR, ITW, MMM, PH and ROK, using actual numbers for companies that have reported and Factset consensus for those that have not. *** Because no corresponding adjustments were applicable in 2016, FTV 2016 non-GAAP measures are equal to the corresponding GAAP measures. **** 2-year stack core growth calculated by adding 2021 core growth of 9.5% and 2022 core growth of 10.1%

Q4/FY 2022: INTELLIGENT OPERATING SOLUTIONS

BROAD-BASED STRENGTH ACROSS THE SEGMENT

\$ in millions





INTELLIGENT **OPERATING SOLUTIONS**

Highlights

FY 2022

- Strong backlog and new product launches driving +DD growth at Fluke
- Record iNet expansion and accelerated software implementations drove EHS upside and built momentum for 2023
- FAL SaaS momentum and productivity value proposition drive +DD growth Q4/FY
- Orders slow as supply chains ease and sales cycles extend, as expected
- +DD core growth drove strong OMX in Q4/FY22


Core G	Growt	h Drivers	
		Q4 2022	FY 2022
FLUKE		Low Teens	LDD
EHS: ISC, I	NTELEX	High Teens	LDD
FACILITY 8		LDD	Low Teens

PORTFOLIO QUALITY AND EXECUTION DRIVE RECORD PERFORMANCE

Q4/FY 2022: PRECISION TECHNOLOGIES

DELIVERED GROWTH AND MARGIN UPSIDE

\$ in millions



🕝 FORTIVE

PRECISION TECHNOLOGIES

Highlights

- Record backlog, share gains and NPIs drive another quarter of DD revenue growth at Tektronix
- Tektronix orders slow as supply chains ease and customers exercise caution, as expected
- Sensing Tech saw strong growth in all major regions despite recent orders decline in industrial and semi markets
- Capacity expansion and improved material availability drove record PacSci EMC growth
- +DD core growth and productivity improvements drove strong OMX

Core Grow	oth Drivers Q4 2022	FY 2022
TEKTRONIX	Mid-20%	Mid-Teens
SENSING	Mid-Teens	Low Teens
PACSI EMC	High 20%	LDD


RECORD OUTPERFORMANCE DRIVEN BY STRENGTH OF BACKLOG AND EXECUTION

6

Q4/FY 2022: ADVANCED HEALTHCARE SOLUTIONS

BROAD-BASED GROWTH ACROSS SEGMENT AS EXPECTED

\$ in millions





ADVANCED HEALTHCARE SOLUTIONS


Highlights

- Core growth acceleration at ASP driven by improvement in elective procedures ex-China
- COVID surges drove decline in China in Q4; headwind to continue in Q1'23
- Increased availability of supply at FHS benefits Q4'22 and FY 2023
- FBS-driven market expansion and share gains building momentum in 2023
- Volume more than offset by F/X and higher than expected inflation

Core Grow	th Drivers Q4 2022	FY 2022
ASP	MSD	LSD
FHS	MSD	LSD
CENSIS	HSD	(LSD)
INVETECH	HSD	MSD

STRONG HEALTHCARE FRANCHISE POISED FOR CONTINUED IMPROVEMENT

FBS IN ACTION SUSTAINING KAIZEN RESULTS



28 Cross-Fortive

 Accelerating culture of performance

Teams...

- Deep engagement with segment leaders and many OpCo presidents
- Driving significant improvements in growth, margin, free cash flow and breakthrough innovations
- >400 employees setting and delivering on high expectations

...Sustaining Meaningful **Project Results, Including:**


CEO KAIZEN

- a 20% improvement in quality
- a 50% reduction in past due orders
- **a 25%** improvement in on time delivery
- **a 50%** improvement in feature release lead time
- **a 80%** improvement in quote turnaround time

ACCELERATING KAIZEN ACTIVITY IN 2023, DRIVING MORE INNOVATION AND PROFITABLE GROWTH ACROSS FORTIVE

2022 SUSTAINABILITY HIGHLIGHTS

ACCELERATING PROGRESS FOR ALL STAKEHOLDERS



🕖 FORTIVE

RECOGNITION

Newsweek's **Most Responsible Companies** 4th consecutive year **** America's most RESPONSIBLE companies 2020-2023 Newsweek

statista 🖍

Environment + Energy Leader 2022 Awards:

 ehsAl Compliance Automation Software



• Fluke ii900 Industrial Acoustic Imager

Intelex ESG
 Management
 Software




FLUKE

DRIVING MEANINGFUL, RESPONSIBLE AND SUSTAINABLE IMPACT FOR ESG ISSUES THAT MATTER MOST TO OUR STAKEHOLDERS

Q4 2022 REVENUE

DOUBLE-DIGIT CORE REVENUE GROWTH IN Q4



S FORTIVE

Q4 HIGHLIGHTS

- ~1.5% M&A contribution, net of Therapy Physics divestiture
- ~4% F/X headwind, better than expected
- Broad-based growth across our businesses in NA and W. Europe
- China up Iow-20% despite COVID surges impacting AHS
- Broad-based growth across all high growth markets

BROAD-BASED GROWTH IN ALL MAJOR REGIONS

Q4 2022 PERFORMANCE SUMMARY

A STRONG FINISH TO 2022





PERFORMANCE HIGHLIGHTS

- Adj. gross margin +50bps driven by favorable price / cost
- +110 bps of adj. OMX
- +230 bps adj. OMX on 2-yr stack
- 11% adj. EPS growth despite higher interest and tax Y/Y (16% normalized for tax)
- Q4 FCF up 62% driven by strong year-end collections
- FY'22 FCF up 28%, 107% conversion

HIGHER REVENUE AND MARGINS CONVERTING INTO MORE CASH

BALANCED 2023 OUTLOOK

REFLECTS CURRENT MACRO ENVIRONMENT AND PROACTIVE POSITIONING



INTELLIGENT OPERATING SOLUTIONS Orders normalize at Fluke, expected to improve 2H

- Enhanced market positions yield DD SaaS growth
- Innovation targeting attractive, high growth segments

3.5% to 5.5% Core Growth +125 bps OMX



PRECISION TECHNOLOGIES

- Strong secular trends create durable growth runway at Tektronix
- Weakening industrial and semi demand at Sensing Tech
- FBS-lean productivity benefits driving strong margin performance

3% to 5% Core Growth +75 bps

75 bps OMX



HIGHLIGHTS

- Less cyclical portfolio driven by recurring and secular drivers
- ~\$350M "excess" Hardware Products backlog de-risk outlook
- DD software growth in 2023
- Price realization remains driver of core growth and OMX, but below 2022 levels
- Productivity initiatives planned in all segments
- FBS-Lean tools drive material and value engineering savings, and opex cost-outs



ADVANCED HEALTHCARE SOLUTIONS

- Hospital labor and productivity challenges expected to continue
- China/Russia headwinds impact Q1/FY growth respectively
- Pricing actions gain traction, beginning to offset inflation

3 to 5% Core Growth +150 bps OMX

WELL-POSITIONED TO NAVIGATE THE EVOLVING MACRO ENVIRONMENT

Q1 AND FY 2023 OUTLOOK

	Q1 2023	FY 2023
REVENUE	\$1,400 to 1,435M	\$5,950 to 6,100M
Core Growth ²	5% to 6.5%	3% to 5.5%
Total Growth	2% to 4%	2% to 4.5%
ADJ. OP. PROFIT ²	\$330 to 345M	\$1,485 to 1,550M
Growth	4% to 9%	5% to 10%
ADJ. OP. PROFIT MARGIN ²	23.5% to 24%	25% to 25.5%
Adjusted OMX	+50 bps OMX	+75 bps OMX
ADJ. EPS Growth	\$0.71 to 0.74 1% to 5% 7% to 11% normalized for interest & tax ¹	\$3.25 to 3.40 3% to 8% 6% to 11% normalized for interest & tax ¹
FREE CASH FLOW	~\$170M ~65%	~\$1,250M 100% to 105%

🕖 FORTIVE

KEY ASSUMPTIONS

Q1: FX ~(2.5)% headwind
FY: FX ~(1)% full year headwind

Q1: Corporate ~\$30MFY: Corporate ~\$125M

 Productivity benefits - \$25-30M actions planned 1H

• Q1: Interest ~\$30M, ETR ~16% • FY: Interest ~\$108M, ETR 16-16.5%

•Share Count: ~357M

• Capex ~1.7% of Sales (\$90M to \$110M)


EXCESS BACKLOG MORE THAN OFFSETS ORDERS DECLINE, CHINA/RUSSIA HEADWINDS IN Q1

H1:H2 REVENUE BRIDGES

OUTLOOK ASSUMES REASONABLE 1H \rightarrow 2H STEP-UP

2022 ACTUAL

2023 OUTLOOK





KEY ASSUMPTIONS

REVENUE

- Volume growth and mix drives 1H → 2H core revenue improvement as order profile improves through year
- F/X becomes a tailwind in 2H versus 1H

EPS

- Disciplined and proactive cost management drives 1H:2H benefit
- EPS seasonality impacted by F/X and interest
- Interest expense expected to decline through 2023 as debt is paid down

MODEST STEP UP IN CORE REVENUE 1H:2H; ACCELERATING CORE GROWTH RATE IN 2H







Resilient Financial Profile: High recurring revenue, leading margins and free cash flow growth



Platform Value Creation: Leadership positions in attractive markets with expanded innovation capabilities



Unleashing the Power of FBS: Continuous improvement culture drives differentiated and sustainable results



Accelerated Compounding: Strong balance sheet and FCF growth position us for capital deployment upside

MORE RESILIENT FINANCIAL PROFILE AND HIGHER FCF POWER A KEY DIFFERENTIATOR



Appendix & Supplemental Reconciliation Data



Q1 AND FY 2023 SEGMENT OUTLOOKS

	IOS	Q1 2023 PT	AHS	IOS	FY 2023 PT	AHS
REVENUE GROWTH Core Total	4% to 5.5% 1.5% to 3%	10% to 11.5% 7.5% to 9%	0.5% to 2% (4)% to (2.5)%	3.5% to 5.5% 3% to 5%	3% to 5% 2.5% to 4.5%	3% to 5% 1% to 3%
ADJ. OP. PROFIT MARGIN ¹	27.5% to 28% +50 bps	24% to 24.5% +150 bps	24% to 24.5% +75 bps	30.5% to 31% +125 bps	25.5% to 26% +75 bps	24.5% to 25% +150 bps
OPCO EXPECTATIONS ²	Fluke: MSD+ EHS: MSD FAL: LSD ³	Tektronix: High- Teens Sensing: LSD PacSci EMC: High- Teens	ASP/Censis: LSD ⁴ FHS: MSD Invetech: (Low-20s) Provation: HSD	Fluke: LSD+ EHS: MSD FAL: LDD	Tektronix: MSD+ Sensing: Flat PacSci EMC: MSD+	ASP/Censis: LSD+ FHS: LSD Invetech: LSD Provation: Mid- Teens+

- 1. Values represent targets based on the mid-point of the guide.
- 2. Core growth based on the mid-point of the guide.
- 3. Reflects Q1'23 headwind related to ServiceChannel customer transition from pass-through to SaaS.
- 4. Reflects Q1'23 headwind related to lower China and Russia volumes.

ADJUSTED GROSS PROFIT AND ADJUSTED GROSS PROFIT MARGIN

\bigcirc	FOR	TIVE

		Three Mo	ed		Twelve Me	onths Ended		
\$ in millions	Decen	nber 31, 2022	Dece	ember 31, 2021	Dece	ember 31, 2022	D	ecember 31, 2021
Revenue (GAAP)	\$	1,529.9	\$	1,374.8	\$	5,825.7	\$	5,254.7
Gross Profit (GAAP)	\$	892.5	\$	794.0	\$	3,363.4	\$	3,007.1
Acquisition-Related Fair Value Adjustments to Inventory		—		0.2		0.7		6.9
Discrete Restructuring Charges		_		0.7		_		0.7
Adjusted Gross Profit (Non-GAAP)	\$	892.5	\$	794.9	\$	3,364.1	\$	3,014.7
Adjusted Gross Profit Margin								
Gross Profit (GAAP) Margin		58.3 9	6	57.8 %		57.7 %	6	57.2 %
Acquisition-Related Fair Value Adjustments to Inventory		c	%	— %		— °	6	0.2 %
Discrete Restructuring Charges		<u> </u>	%	— %		%	6	— %
Adjusted Gross Profit Margin (Non-GAAP)		58.3 9	6	57.8 %		57.7 %	6	57.4 %

ADJUSTED OPERATING PROFIT & ADJUSTED OPERATING PROFIT MARGIN



	Three Months Ended December 31, 2022											Three Months Ended December 31, 2021								
\$ in millions	C	ntelligent perating olutions		Precision chnologies	H	Advanced Healthcare Solutions		Corporate	Total Fortive		Intellige Operation Solution	rating		Precision chnologies	н	dvanced ealthcare Solutions		Corporate	Total Fortive	
Revenue (GAAP)	\$	634.7	\$	553.0	\$	342.2	\$	— \$	1,529.9	\$	579	.8	\$	473.9	\$	321.1	\$	- \$	51,374.8	
Operating Profit (GAAP)	\$	150.4	\$	142.8	\$	34.5	\$	(36.8) \$	290.9	\$	5 93	.6	\$	106.9	\$	26.1	\$	(25.0) \$	201.6	
Acquisition and Other Transaction Costs		1.1		_		2.6		_	3.7		15	.8		_		20.2		_	36.0	
Russia Exit and Wind Down Costs				—		—		0.6	0.6		-	_		_		—		_	—	
Acquisition-Related Fair Value Adjustments to Inventory				_		_			_		-	_		_		0.2		_	0.2	
Amortization of Acquisition-Related Intangible Assets		46.6		2.7		45.5		_	94.8		46	.4		3.7		35.3		—	85.4	
Discrete Restructuring Charges				_		_		—	_		5	.9		2.5		3.8		_	12.2	
Adjusted Operating Profit (Non-GAAP)	\$	198.1	\$	145.5	\$	82.6	\$	(36.2) \$	390.0	\$	5 161	.7	\$	113.1	\$	85.6	\$	(25.0) \$	335.4	
Operating Profit Margin (GAAP)		23.7 %	6	25.8 %	,	10.1 %	6		19.0 %		16	.1 %	6	22.6 %	6	8.1 %	6		14.7 %	
Adjusted Operating Profit Margin (Non-GAAP)		31.2 %	6	26.3 %)	24.1 %	6		25.5 %		27	.9 %	6	23.9 %	6	26.7 %	6		24.4 %	
Incremental Adjusted Operating Profit Margin ^(a)																				
Year-over-year change in Revenue (GAAP)																		9	5 155.1	
Year-over-year change in Adjusted Operating Profit (Non-	GAA	P)																\$	54.6	
Incremental Adjusted Operating Profit Margin (Non-G	AAP	(a)																	35.2 %	
(a) Incremental adjusted operating profit margin is calculated as	the i	ncrease in a	adjust	ed operating	profit	t between tv	wo p	periods, divided	by the increa	se	in adjusted	d rev	/enue	between the	sam	e two period	ds.			

ADJUSTED OPERATING PROFIT & ADJUSTED OPERATING PROFIT MARGIN



			Two	elve Months	: En	ded Decei	mbe	er 31, 2022	Twelve Months Ended December 31, 2021										
<i>\$ in millions</i>	(ntelligent Operating Solutions		Precision Technologies		Advanced Healthcare Solutions		Corporate		Total Fortive		Intelligent Operating Solutions	Precision Technologies		Advanced Healthcare Solutions)		Total Fortive
Revenue (GAAP)	\$	2,466.1	\$	2,038.2	\$	1,321.4	\$. <u> </u>	\$5	,825.7	\$	2,169.4	\$	1,848.9	\$	1,236.4	\$	- 4	5,254.7
Operating Profit (GAAP)	\$	519.4	\$	491.3	\$	107.9	\$	(131.2)	\$	987.4	\$	408.5	\$	408.0	\$	101.9	\$	(105.6) \$	6 812.8
Acquisition and Other Transaction Costs		17.7		_		8.7		_		26.4		30.2		_		29.7		_	59.9
Russia Exit and Wind Down Costs								17.9		17.9		_						_	
Acquisition-Related Fair Value Adjustments to Inventory		_				0.7				0.7		_		_		6.9		_	6.9
Amortization of Acquisition-Related Intangible Assets		184.5		13.5		184.2		_		382.2		163.3		16.4		141.1			320.8
Discrete Restructuring Charges		_		_		_		_		_		5.9		2.5		3.8		_	12.2
Adjusted Operating Profit (Non-GAAP)	\$	721.6	\$	504.8	\$	301.5	\$	(113.3)	\$1	,414.6	\$	607.9	\$	426.9	\$	283.4	\$	(105.6) \$	51,212.6
Operating Profit Margin (GAAP)		21.1 %	6	24.1 %	6	8.2 %	%			16.9 %		18.8 %	6	22.1 %	6	8.2 %	, 0		15.5
Adjusted Operating Profit Margin (Non-GAAP)		29.3 %	6	24.8 %	6	22.8 %	%			24.3 %		28.0 %	6	23.1 %	6	22.9 %	6		23.1
Incremental Adjusted Operating Profit Margin ^(a)																			
Year-over-year change in Revenue (GAAP)																		\$	571.0
Year-over-year change in Adjusted Operating Profit (Non-	GA	AP)																9	5 202.0
Incremental Adjusted Operating Profit Margin (Non-G	AAF) (a)																	35.4
(a) Incremental adjusted operating profit margin is calculated as	the	increase in	adjus	ted operating	prof	fit between t	wo p	periods, divideo	d b	y the increa	se i	in adjusted rev	enue	e between the	sar	me two period	ds.		



TWO YEAR STACK - ADJUSTED OPERATING PROFIT AND ADJUSTED OPERATING PROFIT MARGIN

			Thr	ee Months	End	ed Decen	nber	31, 2022		Three Months Ended December 31, 2020									
\$ in millions	0	telligent perating olutions		Precision chnologies	He	ealthcare Fortive Operating Technologies Hea				Advanced lealthcare Solutions	C	orporate	Total Fortive						
Revenue (GAAP)	\$	634.7	\$	553.0	\$	342.2	\$	_	\$1,529.9	\$	\$	544.9	\$	464.2	\$	315.8	\$	— \$	51,324.9
Acquisition-Related Fair Value Adjustments to Deferred Revenue		_		—		_		_	_			—		—		0.5		_	0.5
Adjusted Revenue (Non-GAAP)	\$	634.7	\$	553.0	\$	342.2	\$	_	\$1,529.9	\$	\$	544.9	\$	464.2	\$	316.3	\$	— \$	51,325.4
Operating Profit (GAAP)	\$	150.4	\$	142.8	\$	34.5	\$	(36.8)	\$ 290.9	\$	5	104.8	\$	89.0	\$	18.0	\$	(27.9) \$	5 183.9
Acquisition and Other Transaction Costs		1.1		—		2.6		—	3.7			0.1		—		14.2		—	14.3
Russia Exit and Wind Down Costs		_				_		0.6	0.6			_		_		_		_	_
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory		_		—		—		—	—			—		—		4.5		—	4.5
Amortization of Acquisition-Related Intangible Assets		46.6		2.7		45.5		_	94.8			37.7		4.2		35.3		_	77.2
Discrete Restructuring Charges								_	_			13.7		9.7		4.2			27.6
Adjusted Operating Profit (Non-GAAP)	\$	198.1	\$	145.5	\$	82.6	\$	(36.2)	\$ 390.0	\$	5	156.3	\$	102.9	\$	76.2	\$	(27.9) \$	5 307.5
Operating Profit Margin (GAAP)		23.7 %	6	25.8 %	D	10.1 %	6		19.0	%		19.2 %	6	19.2 %	6	5.7 %	6		13.9 %
Adjusted Operating Profit Margin (Non-GAAP)		31.2 %	6	26.3 %	5	24.1 %	6		25.5	%		28.7 %	6	22.2 %	6	24.1 %	6		23.2 %



TWO YEAR STACK - ADJUSTED OPERATING PROFIT AND ADJUSTED OPERATING PROFIT MARGIN

			Twe	elve Months	Ene	ded Decer	nber	[.] 31, 2022		Twelve Months Ended December 31, 2020								
\$ in millions	C	ntelligent perating Solutions		Precision chnologies	н	dvanced ealthcare Solutions		orporate	Total Fortive		Intelligent Operating Solutions		Precision Advanced Technologies Healthcare Solutions				orporate	Total Fortive
Revenue (GAAP)	\$	2,466.1	\$	2,038.2	\$	1,321.4	\$	_	\$5,825.7	\$	1,883.7	\$	1,651.3	\$	1,099.4	\$	— \$	4,634.4
Acquisition-Related Fair Value Adjustments to Deferred Revenue		_		_		_		_	_		7.6		_		5.3		_	12.9
Adjusted Revenue (Non-GAAP)	\$	634.7	\$	553.0	\$	342.2	\$	_	\$1,529.9	\$	1,891.3	\$	1,651.3	\$	1,104.7	\$	— \$	4,647.3
Operating Profit (GAAP)	\$	519.4	\$	491.3	\$	107.9	\$	(131.2)	\$ 987.4	\$	317.8	\$	321.7	\$	2.1	\$	(102.2) \$	539.4
Acquisition and Other Transaction Costs		17.7		—		8.7		—	26.4		0.9		0.1		70.6		—	71.6
Russia Exit and Wind Down Costs						_		17.9	17.9		_						_	_
Acquisition-Related Fair Value Adjustments to Deferred Revenue and Inventory		—		—		0.7		—	0.7		7.8		—		19.5		—	27.3
Amortization of Acquisition-Related Intangible Assets		184.5		13.5		184.2		_	382.2		151.1		17.2		141.6		_	309.9
Discrete Restructuring Charges		—		—		—		—	—		13.7		9.7		4.2		—	27.6
Adjusted Operating Profit (Non-GAAP)	\$	721.6	\$	504.8	\$	301.5	\$	(113.3)	\$1,414.6	\$	491.3	\$	348.7	\$	238.0	\$	(102.2) \$	975.8
Operating Profit Margin (GAAP)		21.1 %	6	24.1 %	, D	8.2 %	6		16.9 %		16.9 %	%	19.5 %	, 0	0.2 %	, 0		11.6 %
Adjusted Operating Profit Margin (Non-GAAP)		29.3 %	6	24.8 %	D	22.8 %	6		24.3 %		26.0 %	6	21.1 %	ó	21.5 %	6		21.0 %



	Thre	ee Months Ended	December 31, 20	22	Twelve	Months Ended	December 31,	, 2022
	Intelligent Operating Solutions	Precision Technologies	Advanced Healthcare Solutions	Total Fortive	Intelligent Operating Solutions	Precision Technologies	Advanced Healthcare Solutions	Total Fortive
2021 Adjusted Operating Profit Margin (Non-GAAP)	27.9 %	23.9 %	26.7 %	24.4 %	28.0 %	23.1 %	22.9 %	23.1 %
Core (Non-GAAP)	3.3 %	2.4 %	(4.2)%	0.8 %	2.3 %	1.7 %	(1.7)%	1.2 %
Acquisitions (Non-GAAP)	— %	— %	1.6 %	0.3 %	(1.0)%	— %	1.6 %	— %
2022 Adjusted Operating Profit Margin (Non-GAAP)	31.2 %	26.3 %	24.1 %	25.5 %	29.3 %	24.8 %	22.8 %	24.3 %

ADJUSTED NET EARNINGS FROM CONTINUING OPERATIONS



		Three Mont	hs Ended	Twelve Months Ended			
\$ in millions		December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021		
Net Earnings Attributable to Common Stockholders from Continuing Operations (GAAP) ^(a)	\$	227.2	\$ 167.9	\$ 755.2 \$	5 579.7		
Dividends on the mandatory convertible preferred stock to apply if-converted method ^(a)		—	—		34.5		
Net Earnings from Continuing Operations (GAAP)	\$	227.2	\$ 167.9	\$ 755.2 \$	614.2		
Interest on the Convertible Notes to apply if-converted method ^(b)		—	—	2.1	—		
Tax effect of the Convertible Notes to apply if-converted method ^(c)		—	—	(0.3)	_		
Diluted Net Earnings from Continuing Operations (GAAP)		227.2	167.9	757.0	614.2		
Pretax amortization of acquisition-related intangible assets		94.8	85.4	382.2	320.8		
Pretax acquisition-related items ^(d)		3.7	36.2	27.1	66.8		
Pretax losses from equity investments ^(e)		2.1	3.9	17.3	11.6		
Pretax Russia exit and wind down costs		0.6	—	17.9	—		
Pretax (gain) loss on sale of business		1.8	—	(0.5)	—		
Pretax interest expense on Convertible Notes to reverse the if-converted method ^(b)		_	_	(2.1)	—		
Pretax loss on debt extinguishment, net of gain on Vontier common stock		_	_	_	47.9		
Pretax gain on litigation resolution		_	(3.9)	_	(29.9)		
Pretax non-cash interest expense associated with our 0.875% Convertible Notes		_	7.2	_	29.1		
Pretax discrete restructuring charges		_	12.2	—	12.2		
Tax effect of the adjustments reflected above ^(c)		(17.2)	(20.9)	(65.9)	(76.3)		
Adjusted Net Earnings from Continuing Operations (Non-GAAP)	\$	313.0	\$ 288.0	\$ 1,133.0 \$	996.4		

(a) On July 1, 2021, all outstanding shares of our MCPS converted at a rate of 14.0978 common shares per share of preferred stock into an aggregate of approximately 19.4 million shares (net of fractional shares). The MCPS were anti-dilutive for the year ended December 31, 2021 and as such GAAP net earnings per share was calculated using net earnings from continuing operations attributable to common stockholders.

(b) Beginning with our adoption of ASU 2020-06 on January 1, 2022 we assumed share settlement of our outstanding Convertible Notes under the if-converted method when calculating GAAP diluted net earnings per share. Since we settled the Convertible Notes in cash on February 15, 2022 and no common share conversion occurred, we have reversed the impacts of applying the if-converted method and included the actual cash interest expense in calculating the adjusted net earnings per share.

(c) The dividend on the MCPS is not tax deductible. The gain on the fair value change in Vontier common stock had no tax effect. The tax effect of the adjustments includes all other line items.

(d) Includes pretax Transaction Costs and acquisition-related fair value adjustments to inventory related to significant acquisitions.

(e) Includes pretax losses from equity method investments and, an \$8.1 million pretax impairment loss on an equity investment in the third quarter of 2022.

ADJUSTED DILUTED NET EPS	Dec	ree Months cember , 2022	Ended ^(a) December 31, 2021	De	elve Month cember I, 2022	ns Ended ^(a) December 31, 2021
Net Earnings Attributable to Common Stockholders from Continuing Operations (GAAP) (b)	\$	0.64 \$	0.46	\$	2.10	\$ 1.65
Dividends on the mandatory convertible preferred stock to apply if-converted method ^(b)		—	—		—	0.10
Assumed dilutive impact on the Diluted Net Earnings Per Share Attributable to Common Stockholders if the MCPS Converted Shares had been outstanding ^(b)		_	_		_	(0.05)
Net Earnings from Continuing Operations (GAAP)		0.64	0.46		2.10	1.70
Interest on the Convertible Notes to apply if-converted method ^(c)		_	_		_	
Tax effect of the Convertible Notes to apply if-converted method (c)			_		_	_
Diluted Net Earnings Per Share from Continuing Operations (GAAP)		0.64	0.46		2.10	1.70
Pretax amortization of acquisition-related intangible assets		0.27	0.24		1.06	0.89
Pretax acquisition-related items ^(d)		0.01	0.10		0.08	0.19
Pretax losses from equity investments ^(e)		0.01	0.01		0.05	0.03
Pretax Russia exit and wind down costs		_	_		0.05	
Pretax (gain) loss on sale of business		0.01	_		_	_
Pretax interest expense on Convertible Notes to reverse if-converted method (c)		—	—		—	_
Pretax loss on debt extinguishment, net of gain on Vontier common stock		—	_		_	0.13
Pretax gain on litigation resolution		—	(0.01)		_	(0.08)
Pretax non-cash interest expense associated with our 0.875% Convertible Notes		_	0.02		_	0.08
Pretax discrete restructuring charges			0.03		_	0.03
Tax effect of the adjustments reflected above ^(f)		(0.05)	(0.06)		(0.19)	(0.21)
Adjusted Diluted Net Earnings Per Share from Continuing Operations (Non-GAAP)	\$	0.88 \$	0.79	\$	3.15	\$ 2.75
(shares in millions)						
Average common diluted stock outstanding		356.7	362.9		360.8	352.3
MCPS Converted Shares ^(a)		—	_		_	9.9
Convertible Notes - if converted shares (c)					(1.6)	
Adjusted average common stock and common equivalent shares outstanding		356.7	362.9		359.2	362.2

(a) Each of the per share adjustments below was calculated assuming the MCPS Converted Shares had converted at the beginning of the period prior to their conversion on July 1, 2021. The 0.875% convertible notes did not have an impact on the adjusted diluted shares outstanding.

(b) Prior to their conversion on July 1, 2021, the MCPS were anti-dilutive for the year ended December 31, 2021, and as such GAAP net earnings per share was calculated using net earnings from continuing operations attributable to common stockholders.

(c) Beginning with our adoption of ASU 2020-06 on January 1, 2022 we assumed share settlement of our outstanding Convertible Notes under the if-converted method when calculating GAAP diluted net earnings per share. Since we settled the Convertible Notes in cash on February 15, 2022 and no common share conversion occurred, we have reversed the impacts of applying the if-converted method and included the actual cash interest expense in calculating the adjusted net earnings per share. The impact of the after tax adjustment to GAAP diluted net earnings per share for the twelve months ended December 31, 2022 rounds to zero.

(d) Includes pretax Transaction Costs and acquisition-related fair value adjustments to inventory related to significant acquisitions.

(e) Includes pretax losses from equity method investments and, an \$8.1 million pretax impairment loss on an equity investment in the third quarter of 2022.

(f) The dividend on the MCPS is not tax deductible and the convertible note interest is calculated on a net of tax basis. The gain on the fair value change in Vontier common stock had no tax effect. The tax effect of the adjustments includes all other line items.

The sum of the components of adjusted diluted net earnings per share may not equal due to rounding.



FORECASTED ADJUSTED DILUTED NET EPS FROM CONTINUING OPERATIONS



	Three Months March 31, 2	Twelve Months Ending December 31, 2023			
	 Low	High		Low	High
Forecasted Net Earnings Per Share from Continuing Operations (GAAP)	\$ 0.47 \$	0.50	\$	2.30 \$	2.45
Anticipated pretax amortization of acquisition-related intangible assets	0.26	0.26		1.04	1.04
Anticipated pretax losses from equity investments	—	—		0.03	0.03
Anticipated pretax discrete restructuring charges	0.03	0.03		0.06	0.06
Tax effect of the adjustments reflected above	 (0.05)	(0.05)		(0.18)	(0.18)
Forecasted Adjusted Diluted Net Earnings Per Share from Continuing Operations	\$ 0.71 \$	0.74	\$	3.25 \$	3.40

The sum of the components of forecasted adjusted diluted net earnings per share from continuing operations may not equal due to rounding.

FREE CASH FLOW CONVERSION RATIO - TWELVE MONTHS ENDED December 31, 2022 AND December 31, 2021 (in millions)



Three Months Ended Twelve Months Ended December 31, 2022 September 30, 2022 July 1, 2022 April 1, 2022 December 31, 2022 464.2 \$ 329.8 \$ 294.4 \$ 214.8 **Operating Cash Flows from Continuing Operations (GAAP)** \$ \$ 1,303.2 Less: purchases of property, plant & equipment (capital expenditures) from continuing operations (GAAP) (36.1) (22.5)(18.4) (95.8) (18.8) Free Cash Flow from Continuing Operations (Non-GAAP) 428.1 \$ 276.0 \$ \$ 307.3 \$ 196.0 \$ 1,207.4 Net Earnings from Continuing Operations (GAAP) \$ 227.2 \$ 173.0 \$ 189.9 \$ 165.1 \$ 755.2 Free Cash Flow Conversion Ratio (Non-GAAP) 160 % 119 % 160 % 188 % 162 % Adjusted Net Earnings from Continuing Operations (Non-GAAP) 313.0 \$ 283.8 \$ 255.1 1,133.0 \$ 281.1 \$ \$ 98 % 77 % Adjusted Free Cash Flow Conversion Ratio (Non-GAAP) 137 % 107 % 108 % **Revenue (GAAP)** \$ 5,825.7 Free Cash Flow Margin (Non-GAAP) 20.7 %

				Three Mor	nths	Ended				Twelve Months Ended	T١	welve Months Ended
	Decen	nber 31, 2021	0	ctober 1, 2021		July 2, 2021		April 2, 2021	De	ecember 31, 2021	Dece	ember 31, 2016 ^(a)
Operating Cash Flows from Continuing Operations (GAAP)	\$	287.0	\$	262.9	\$	291.0	\$	152.0	\$	992.9	\$	1,136.9
Less: purchases of property, plant & equipment (capital expenditures) from continuing operations (GAAP)		(22.0)		(10.9)		(8.7)		(8.4)		(50.0)		129.6
Free Cash Flow from Continuing Operations (Non-GAAP)	\$	265.0	\$	252.0	\$	282.3	\$	143.6	\$	942.9	\$	1,007.3
Net Earnings from Continuing Operations (GAAP)	\$	167.9	\$	152.6	\$	182.0	\$	111.7	\$	614.2		
Free Cash Flow Conversion Ratio (Non-GAAP)		158 %	6	165 %)	155 %	6	129 %		154 %		
Adjusted Net Earnings from Continuing Operations (Non-GAAP)	\$	288.0	\$	240.5	\$	238.8	\$	229.1	\$	996.4		
Adjusted Free Cash Flow Conversion Ratio (Non-GAAP)		92 %	6	105 %)	118 %	6	63 %		95 %		
Revenue (GAAP)											\$	6,224.3
Free Ceek Flow Merrin (Nen CAAD)												40.0.0/

Free Cash Flow Margin (Non-GAAP)

^(a) Includes carve-out amounts from Danaher and includes the A&S and Vontier businesses

CORE REVENUE GROWTH

Components of Revenue Growth	Three Months Ended December 31, 2022	Twelve Months Ended December 31, 2022
Total Fortive		
Total Revenue Growth (GAAP)	11.3 %	10.9 %
Core (Non-GAAP)	13.8 %	10.1 %
Acquisitions (Non-GAAP)	1.4 %	3.9 %
Impact of currency translation (Non-GAAP)	(3.9)%	(3.1)%
Intelligent Operating Solutions		
Total Revenue Growth (GAAP)	9.5 %	13.7 %
Core (Non-GAAP)	13.1 %	12.0 %
Acquisitions (Non-GAAP)	— %	4.6 %
Impact of currency translation (Non-GAAP)	(3.6)%	(2.9)%
Precision Technologies		
Total Revenue Growth (GAAP)	16.7 %	10.2 %
Core (Non-GAAP)	20.4 %	13.2 %
Acquisitions (Non-GAAP)	— %	— %
Impact of currency translation (Non-GAAP)	(3.7)%	(3.0)%
Advanced Healthcare Solutions		
Total Revenue Growth (GAAP)	6.6 %	6.9 %
Core (Non-GAAP)	5.3 %	2.1 %
Acquisitions (Non-GAAP)	5.9 %	8.4 %
Impact of currency translation (Non-GAAP)	(4.6)%	(3.6)%
TWO YEAR STACK CORE GROWTH		
Components of Revenue Growth		Twelve Months Ended December 31, 2021
<u>Total Fortive</u>		
Total Revenue Growth (GAAP)		13.4 %
Core (Non-GAAP)		9.5 %
Acquisitions (Non-GAAP)		2.4 %
Impact of currency translation (Non-GAAP)		1.5 %
Two-year stack core growth ^(a)		19.6 %
(a) 2-year stack core growth calculated by adding 2021 core growth of 9.5% and 2022 core growth of 10.1%		28

ADJUSTED EFFECTIVE TAX RATE



	Three Mo	nths Er	Twelve Months Ended					
Dec	December 31, 2022		December 31, 2021		cember 31, 2022	De	ecember 31, 2021	
\$	257.0	\$	175.7	\$	873.5	\$	677.5	
	(29.8)		(7.8)		(118.3)		(63.3)	
	11.6 %	6	4.4 %		13.5 %	6	9.3 %	
\$	257.0	\$	175.7	\$	873.5	\$	677.5	
	94.8		85.4		382.2		320.8	
	3.7		36.2		27.1		66.8	
	2.1		3.9		17.3		11.6	
	0.6		—		17.9		—	
	1.8		—		(0.5)		—	
			—		—		47.9	
			(3.9)		—		(29.9)	
			7.2		—		29.1	
			12.2	_	—		12.2	
\$	360.0	\$	316.7	\$	1,317.5	\$	1,136.0	
	(17.2)		(20.9)		(65.9)		(76.3)	
\$	(47.0)	\$	(28.7)	\$	(184.2)	\$	(139.6)	
	13.1 %	6	9.1 %		14.0 %	6	12.3 %	
	\$ \$ \$	December 31, 2022 \$ 257.0 (29.8) (11.6 %) \$ 257.0 94.8 3.7 94.8 3.7 2.1 0.6 1.8 \$ 360.0 \$ (17.2) \$ (47.0)	December 31, 2022 December 31, 2022 \$ 257.0 \$ (29.8) 11.6 % 94.8 94.8 3.7 2.1 0.6 1.8 94.8 1.8 5 360.0 \$ (17.2)	2022 2021 \$ 257.0 \$ 175.7 (29.8) (7.8) 11.6 % 4.4 % \$ 257.0 \$ 175.7 94.8 85.4 3.7 36.2 2.1 3.9 0.6 1.8 (3.9) 7.2 12.2 \$ 360.0 \$ 316.7 \$ 17.2) (20.9) \$ (47.0) \$ (28.7)	December 31, 2022 December 31, 2021 December 32, 2021 December 33, 2021 December 33, 2021	December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2022 \$ 257.0 \$ 175.7 \$ 873.5 (29.8) (7.8) (118.3) (118.3) 11.6 % 4.4 13.5 94.8 85.4 382.2 3.7 36.2 27.1 2.1 3.9 17.3 0.6 17.9 1.8 (0.5) 7.2 7.2 12.2 \$ 360.0 \$ 316.7 \$ \$ 360.0 \$ 316.7 \$ \$ 360.0 \$ 316.7 \$ \$ 360.0 \$ 316.7 \$ \$ 360.0 \$ 316.7 \$ \$ 360.0 \$ 316.7 \$ \$ (17.2) (20.9) \$ (184.2)	December 31, 2022 December 31, 2021 December 31, 2022 December 31, 202 December 32 December 32 December 32 December 32 <	

